Status:
COMPLETED
Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease
Lead Sponsor:
Duke University
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
5-12 years
Phase:
PHASE1
Brief Summary
The proposed research study is a cross-sectional study enrolling young children with sickle cell disease between 5 and 12 years of age. They will be screened as outpatients for consent to perform pulm...
Eligibility Criteria
Inclusion
- children aged 5 to 12 years of age with sickle cell disease (HbSS, HbSC, HbS beta plus thalassemia, HbS beta zero thalassemia, and HbS OArab)
- established patients within the Duke Pediatric Sickle Cell Clinic.
- Subjects must have been full-term at birth
- any race or gender
Exclusion
- significant chromosomal/congenital anomalies
- hemodynamically significant congenital heart disease (arrhythmia requiring medication, defects with chronic hypoxia, single ventricle physiology, heart failure)
- any child within 3 weeks of a respiratory tract infection, an asthma attack, an episode of ACS or of a vaso-occlusive or hemolytic crisis.
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01895998
Start Date
August 1 2013
End Date
April 1 2014
Last Update
December 3 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Medical Center
Durham, North Carolina, United States, 27710